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Abstract Mycophenolate mofetil (MMF) is widely used
to prevent acute rejection in adults after renal, cardiac,
and liver transplantation. This study investigated the
safety, tolerability, and pharmacokinetics of MMF sus-
pension in pediatric renal allograft recipients. One hun-
dred renal allograft recipients were enrolled into three
age groups (33 patients, 3 months to <6 years; 34 pa-
tients, 6 to <12 years; 33 patients, 12 to 18 years). 
Patients received MMF 600 mg/m2 b.i.d. concomitantly
with cyclosporine and corticosteroids with or without an-
tilymphocyte antibody induction. One year after trans-
plantation, patient and graft survival (including death)
were 98% and 93%, respectively. Twenty-five patients
(25%) experienced a biopsy-proven (Banff grade border-
line or higher) or presumptive acute rejection within the
first 6 months post-transplantation. Analysis of pharma-
cokinetic parameters for mycophenolic acid (MPA) and
mycophenolic acid glucuronide showed no clinically sig-
nificant differences among the age groups. The dosing
regimen of MMF 600 mg/m2 b.i.d. achieved the targeted
early post-transplantation MPA 12-h area under concen-
tration-time curve (AUC0–12) of 27.2 µg h per ml. Ad-
verse events had similar frequencies among the age
groups (with the exception of diarrhea, leukopenia, 
sepsis, and anemia, which were more frequent in the 
<6 years age group) and led to withdrawal of MMF 
in about 10% of patients. Administration of MMF 
600 mg/m2 b.i.d. is effective in prevention of acute rejec-
tion, provides predictable pharmacokinetics, and is asso-
ciated with an acceptable safety profile in pediatric renal
transplant recipients.
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Introduction
Mycophenolate mofetil (MMF) is a morpholinoethyl ester
of mycophenolic acid (MPA) that inhibits inosine mono-
phosphate dehydrogenase, an enzyme required for purine
biosynthesis [1, 2, 3, 4, 5, 6, 7]. The immunosuppressive
efficacy of MMF in preventing acute rejection has been
demonstrated in clinical trials of adult patients after renal
[8, 9, 10], cardiac [11], or liver [12] transplantation, when
used in conjunction with cyclosporine and corticosteroids.
An earlier dose-ranging pilot study evaluated the safe-
ty and tolerability of MMF for the prevention of acute re-
jection in pediatric renal allograft recipients and provided
initial pharmacokinetic data for the active metabolite
MPA, and for the inactive metabolite mycophenolic acid
glucuronide (MPAG), in pediatric patients [13]. The cur-
rent study presents the 12-month results from a second
clinical trial aimed at evaluating the safety, tolerability,
and pharmacokinetics of MMF suspension at the recom-
mended pediatric dose. The anticipated follow-up period
for the entire study is 36 months.
Patients and methods
Patients
This is an ongoing, multicenter, open-label, single-arm study of
MMF oral suspension in pediatric renal transplant patients. Pa-
tients included in the study were male or female, aged 3 months to
18 years, weighing at least 5.4 kg (approximately 12 lb). They
were recipients of a first or second ABO-compatible single-organ
(kidney) allograft from a living or cadaver donor, were able to tol-
erate oral medication, and were without any contraindication for
the co-administration of cyclosporine and corticosteroids.
Exclusion criteria included the following: active systemic infec-
tion; an absolute neutrophil count <1300 granulocytes/mm3 at
study entry; active peptic ulcer disease; severe diarrhea or other
gastrointestinal disorder that might interfere with absorption of oral
medication; serologic evidence of human immunodeficiency virus
(HIV) or hepatitis B virus (HBV) infection; pregnancy/breast-feed-
ing; history of malignancy (excluding adequately treated basal or
squamous cell skin carcinoma); recurrent focal segmental glomeru-
lar sclerosis; prior exposure to MMF; or use of tacrolimus.
Monitoring for renal function, rejection episodes, adverse
events (AEs), opportunistic infections, and malignancy was begun
at the time of transplantation and at regularly scheduled clinical
assessments thereafter. Renal transplant biopsies were performed,
unless medically contraindicated, to confirm the diagnosis of acute
rejection.
Patients were permitted to withdraw from the study at any time
for any reason. If patients withdrew, they were to be followed for
a period of 36 months after transplantation for rejection, graft loss,
death, malignancies, and opportunistic infections.
Drug treatment
The dosage of MMF oral suspension was 600 mg/m2 b.i.d. (up to
1 g b.i.d.), used concomitantly with cyclosporine and corticoste-
roids according to each center’s standard of care. Antilymphocyte
antibody induction therapy was also allowed according to center
practice.
The targeted MPA area under the concentration-time curve
(AUC) was derived from studies in adults that demonstrated the
safety and efficacy of the 1 g b.i.d. MMF dose in that population
[14]. Body surface area (BSA) in the current pediatric trial was
calculated using the Mosteller equation [15], and individual dos-
ing was adjusted, based on changes in BSA, as needed.
Administration of high-dose corticosteroids and the use of an-
tilymphocyte antibody preparations were permitted, according to
center-specified regimens and at the discretion of the investigator,
for the treatment of biopsy-confirmed/presumptive acute rejection
episodes. Nine months after transplantation, a switch from the sus-
pension to the capsule formulation of MMF was permitted if pro-
tocol-defined criteria were satisfied (BSA ≥1.25 m2, patient able
to swallow capsules, and more convenient for patient).
Pharmacokinetics
At selected study sites, plasma samples were collected for 12-h
pharmacokinetic profiles on day 7 and at months 3, 9, 24, and 36.
Samples were drawn at 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 8, and 12 h
after the dose was given. Blood samples were also requested dur-
ing serious adverse events or acute rejection episodes (pharmaco-
kinetic AE samples).
Ethics and quality control
The study was conducted in full compliance with the Declaration
of Helsinki (as amended in Tokyo, Venice, and Hong Kong) or in
compliance with the laws and regulations of the country in which
the research was conducted, whichever provided greater protection
to the patient. Written informed consent was obtained from all 
patients or the patient’s parent or legal guardian, following expla-
nation of the aims, methods, and anticipated benefits as well as
potential hazards of the study. Data quality was monitored
throughout the course of the study.
Safety and efficacy analysis
All enrolled patients who received at least one dose of study drug
were included in the safety analyses. The primary efficacy param-
eter was the proportion of patients experiencing a biopsy-proven
rejection (BPR) episode within the first 6 months post-transplanta-
tion. Additional efficacy endpoints were the proportion of patients
who lost their graft by 6 and 12 months, the proportion of patients
who died at 6 and 12 months, and the proportion of patients who
received anti-rejection therapy at 6 months post-transplantation. A
BPR episode was defined as a core renal biopsy demonstrating a
severity that was borderline or higher, according to the Banff sche-
ma for classification of renal allograft pathology [16]. Presump-
tive rejection included those patients receiving a protocol-defined
full course of immunosuppressive therapy for rejection when bi-
opsy confirmation was not possible. Graft loss was defined as
chronic dialysis (>42 consecutive days), transplant nephrectomy,
or re-transplantation.
Pharmacokinetic statistics
Pharmacokinetic parameters were assessed using Analysis of Vari-
ance where appropriate. Descriptive summary statistics (mean, stan-
dard deviation, and number of patients) are presented in Table 1 for
pharmacokinetic parameters, as well as plasma concentrations by
each sampling time and by the three age groups. Pharmacokinetic
AE samples for selected serious adverse events [including leukope-
nia, vomiting, cytomegalovirus (CMV), and diarrhea] and for all re-
jection episodes were compared with mean data at similar time
points from patients having 12-h pharmacokinetic profiles. Plasma
concentrations of MPA and MPAG were determined by PHARMout
Laboratories, Inc. (Sunnyvale, California) using a sensitive and spe-
cific high-performance liquid chromatography method [17]. The
limit of quantification was 0.100 µg/ml for MPA and 4.00 µg/ml for
MPAG (MPA equivalent 2.38 µg/ml, determined by multiplying all





A total of 100 patients, 68 males and 32 females, were
enrolled in the study into 3 age groups: 3 months to 
<6 years, 6 years to <12 years, and 12 years to 18 years.
The distribution of patients by sex and race was similar
across age groups. Sixty-four patients were from North
America, 4 from Australia, and 32 from Europe. At least
one patient was represented in each age year through to
age 18. The most common reason for renal failure for
patients enrolled in the study was congenital abnormality
(48%), followed by glomerulonephritis (26%). For most
patients (87%), this was their first renal transplant, and
54% of grafts were from a living related donor. The
number of A+B+DR mismatches was distributed evenly
across age groups. The majority of patients received an-
tibody induction therapy (73%), which consisted primar-
ily of antithymocyte globulin (54%), but also included
muromonab-CD3 (OKT3, 9%), daclizumab (7%), and
antilymphocyte globulin (3%).
Of 100 patients enrolled, 72 were ongoing after 
the first 12 months and 28 withdrew before completing 
12 months. Ten of the 28 patients withdrew prematurely
because they needed medication that was prohibited by
the study protocol, comprising patients switched to 
tacrolimus to avoid side effects of cyclosporine (n=5),
patients experiencing chronic rejection (n=3), and pa-
tients switched to cyclophosphamide (n=2) for recurrent
focal segmental glomerulosclerosis. Adverse events ac-
counted for an additional ten withdrawals (see Safety
and tolerability Section below for details).
Efficacy
Twenty-five patients (25%) experienced either a first
BPR (23 patients) or a presumptive rejection (two pa-
tients) within the first 6 months of the study. These 
patients were evenly distributed across the age groups
studied (Table 2). Ninety-two percent of rejection epi-
sodes were confirmed by biopsy. Twenty-one percent of
patients (15/73) who received antibody induction therapy
experienced a rejection. Patients who did not receive in-
Table 1 Mean computed phar-
macokinetic parameters of
mycophenolic acid by age and
time after transplantation. Phar-
macokinetic parameters (Tmax
time to maximum concentra-
tion, Adjusted Cmax maximum
concentration adjusted to a
dose of 600 mg/m2, Adjusted
AUC0–12 12-h area under con-
centration-time curve adjusted
to a dose of 600 mg/m2) are 
expressed as mean ±SD with
95% confidence intervals in 
parentheses. P value indicates
the significance of differences
among the three major age
groups (NS not significant,
P>0.05). The <2 years group is
a subset of the <6 years group
and no separate statistical com-
parisons were made
Time after Age group n Tmax Adjusted Adjusted AUC0–12
transplantation (h) Cmax (µg/ml) (µg h per ml)
Day 7 <6 years 17 1.63±2.85 13.2±7.16 27.4±9.54 (22.8–31.9)
6 to <12 years 16 0.940±0.546 13.1±6.30 33.2±12.1 (27.3–39.2)
12 to 18 years 21 1.16±0.830 11.7±10.7 26.3±9.14 (22.3–30.3)a
P value NS NS NS
<2 years 6 3.03±4.70 10.3±5.80 22.5±6.68 (17.2–27.8)
Month 3 <6 years 15 0.989±0.511 22.7±10.1 49.7±18.2
6 to <12 years 14b 1.21±0.532 27.8±14.3 61.9±19.6
12 to 18 years 17 0.978±0.484 17.9±9.57 53.6±20.2c
P value NS NS NS
<2 years 4 0.725±0.276 23.8±13.4 47.4±14.7
Month 9 <6 years 12 0.869±0.479 30.4±9.16 60.9±10.7
6 to <12 years 11 1.12±0.462 29.2±12.6 66.8±21.2
12 to 18 years 14 1.07±0.518 18.1±7.29 56.7±14.0
P value NS 0.004 NS
<2 years 4 0.604±0.208 25.6±4.25 55.8±11.6
a n=20
b Data for one patient were unavailable because of a sampling error
c n=16
Table 2 Summary of first 
biopsy-proven rejection (BPR)
or presumptive rejection during
the first 6 months after trans-
plantation (pediatric criteria).
Numbers, with percentages in
parentheses, are the results of
intent-to-treat analysis using 
local site biopsy readings
BPR/presumptive rejection Number of rejections (%) by age group
<6 years 6 to <12 years 12 to 18 years Total
(n=33) (n=34) (n=33) (n=100)
Borderline 2 (6.1)a 1 (2.9) 3 (9.1)b 6 (6)a
Grade I 2 (6.1) 7 (20.6) 2 (6.1) 11 (11)
Grade IIA 1 (3.0) 1 (2.9) 2 (6.1) 4 (4)
Grade IIB 0 0 2 (6.1) 2 (2)
Grade III 0 0 0 0
Total BPR 5 (15.2) 9 (26.5) 9 (27.3) 23 (23)
BPR or presumptive rejection 7 (21.2) 9 (26.5) 9 (27.3) 25 (25)
a One patient was treated for presumptive rejection and later experienced borderline rejection; this pa-
tient is counted as presumptive rejection in this table
b Two patients had a second rejection episode with a Banff score of grade III; these are not recorded
in the grade III events in this table
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duction therapy had a proportionally higher rejection rate
(10/27, 37%).
Between 6 and 12 months after transplantation, an 
additional four patients experienced their first BPR. At 
1 year, five patients experienced graft loss (two had in-
duction therapy) and two patients died (with functioning
grafts), resulting in a graft survival rate of 93%. Of five
graft losses, three were from patients in Europe, and two
were from US patients. Both of the deaths occurred in
US patients.
Creatinine clearances, calculated by the Schwartz
method [18] as an index of renal function, are shown in
Table 3. 
Safety and tolerability
Eighty-one of the 100 patients (81%) received the study
drug for at least 6 months, and 72 (72%) were on the
study drug for at least 1 year. The mean dose of oral
MMF through the first year on study drug was balanced
across age groups: 524, 551, and 542 mg/m2 b.i.d. for the
groups aged <6 years, 6 to <12 years, and 12 to 18 years,
respectively.
All patients experienced at least one AE during the
first year (Table 4). Eighty-one patients reported AEs
that were deemed by the investigator to be possibly or
probably related to the study drug. The proportion of pa-
tients reporting AEs was generally similar across age
groups for most AEs reported; however, there was a
trend toward more frequent diarrhea and leukopenia in
the two younger age groups (Table 4).
As mentioned above, ten patients (10%) withdrew
from the study because of AEs, and their numbers were
balanced across the age groups. The AEs that resulted in
premature withdrawal were thrombosis of the renal 
artery and/or renal vein (two patients), graft thrombosis,
Epstein-Barr virus infection, diarrhea (two patients),
post-transplantation lymphoproliferative disorder/ane-
mia, anorexia/intermittent abdominal pain, thrombocyto-
penia, and CMV viremia, all in one patient each. The re-
maining patient who withdrew because of AEs did so be-
cause of diarrhea, decreased appetite, nausea, and ab-
dominal discomfort. In seven of these patients, the AEs
resulting in withdrawal were considered by the investi-
gator to be possibly or probably related to the study
drug.
Forty-nine patients (49%) experienced AEs that re-
sulted in MMF dose reduction or interruption. The ma-
jority of AEs resulting in dose reduction (60%) or dose
interruption (66%) had their onset during the first 
3 months of treatment. The AEs that most frequently
resulted in dose reduction or interruption (in ≥5% of all
patients) were leukopenia (22%), diarrhea (13%), sep-
sis (CMV, infections) (10%), anemia (6%), abdominal
pain (5%), and fever (5%). The overall incidence of op-
portunistic infections (OIs) was 48%; the distribution
of OIs was generally similar across age, sex, and racial
subgroups, with the exception of mucocutaneous Can-
dida infection, which had a higher incidence in the
youngest age group. Overall, CMV viremia was the
most frequent OI, being reported in 22% of the pa-
tients.
Two patients died, one of hemorrhagic pancreatitis
and the other of pulmonary embolus. Neither of these
events was deemed by the investigator to be related to
MMF. One malignancy (post-transplantation lymphopro-
liferative disease) was reported approximately 9 months
after transplantation and resolved completely after dis-
continuation of MMF and reduction of other immuno-
suppressants.
Pharmacokinetic data
Fifty-five patients were included in the pharmacokinetic
analysis at day 7. MPA plasma concentrations peaked
approximately 1 h post-dose. In the early post-transplan-
tation period (day 7), the mean dose-adjusted MPA max-
imum concentration (Cmax) was 12.6±8.3 µg/ml, and the
Table 3 Summary of creatinine
clearance (ClCr) by age group
and time after transplant. Creat-
inine clearances (expressed as
ml/min per 1.73 m2) are given
as mean values ±SD and range
Time Parameter <6 years 6 to <12 years 12 to 18 years
Day 7 Patients in study 32 33a 31
Mean ClCr 102±51.9 98.9±60.4 71.9±52.3
ClCr range 7.95–222 9.23–302 15.1–147
Month 3 Patients in study 32 32 25
Mean ClCr 92.8±30.7 92.2±37.5 82.0±26.1
ClCr range 38.5–156 26.5–193 45.7–143
Month 6 Patients in study 31a 30 21
Mean ClCr 91.4±49.2 89.1±32.8 85.3±23.5
ClCr range 27.5–310 44.8–205 50.0–139
Month 9 Patients in study 30 28 20
Mean ClCr 91.0±34.1 97.3±39.6 89.8±41.1
ClCr range 29.7–180 33.2–208 7.06–165b
Month 12 Patients in study 28 27 18
Mean ClCr 91.3±35.6 88.2±25.8 90.9±26.3
ClCr range 28.8–189 45.6–150 37.0–134
a Data were missing for one 
patient in this group at this time
point
b One patient was on dialysis
because of graft rejection at
this time point, with a serum
creatinine value of 12.50 mg/dl
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mean dose-adjusted MPA AUC0–12 was 28.7±10.5 µg h
per ml (95% confidence intervals 25.9–31.6). Table 1
lists the mean computed MPA pharmacokinetic parame-
ters by age and time. There were no statistically signifi-
cant differences (P>0.05) in mean MPA plasma concen-
trations or mean computed parameters among the age
groups given MMF suspension, with the exception of the
dose-adjusted MPA Cmax at month 9 in the oldest age
group (Table 1). The mean dose-adjusted MPA AUC0–12
for all patients was similar to the desired target MPA
(27.2 µg h per ml) at day 7, and increased by 90% be-
tween day 7 and month 3 and by 11% between month 3
and month 9. A statistically significant difference was
noted across the age groups for the mean dose-adjusted
MPAG AUC0–12 at all time points, with values of this in-
active metabolite increasing from the youngest to oldest
groups, although large standard deviations were noted in
all the groups. In retrospectively defined subgroup ana-
lyses, the target MPA AUC0–12 was achieved by each
age, gender, and ethnic subgroup, although the number
of representative patients was limited in some of the sub-
groups.
No associations were observed between low MPA and
MPAG plasma concentrations and the incidence of acute
rejection. Similarly, no associations were found between
adverse events and pharmacokinetic parameters. MPA
and MPAG concentrations calculated from pharmacoki-
netic AE samples were generally similar to the 12-h
pharmacokinetic profile. This study, however, was not
designed to formally examine an association of pharma-
cokinetic and pharmacodynamic parameters.
Discussion
This study demonstrates the efficacy, safety, and pharma-
cokinetics of MMF (600 mg/m2 b.i.d.) in pediatric pa-
tients. The incidence of biopsy-proven rejection was
similar across the three age groups and compares favor-
ably with rejection rates observed in adult renal trans-
plant patients at 6 months post-transplantation [8, 9, 10].
The majority of rejection episodes were borderline or
grade I in severity, following the Banff criteria. The
overall patient survival rate was 98%, and graft survival
(excluding death) was 95% at 12 months.
US Registry data show that 12-month graft survival
rates in children have been improving. The current rate
(85%–94%) is similar to that observed in adults (83%–
94%). European Registry data show that 12-month graft
survival rates in children have slightly improved from
the late 1980s (61%–78%) to the late 1990s (66%–81%).
These rates are now similar to those of adults in Europe
(75%–83%), with the exception of poorer graft survival
rates in the youngest patients (<3 years of age). Higher
rates of vascular thrombosis account for the increased
graft loss in these patients [19].
Table 4 Summary of adverse event (AEs) by specific event and age group
Specific adverse event Number of adverse events (%) by age group
<6 years 6 to <12 years 12 to 18 years Total
(n=33) (n=34) (n=33) (n=100)
Diarrhea
All cases 29 (87.9) 23 (67.6) 10 (30.3) 62 (62)
Severe 3 (9.1) 0 0 3 (3)
Possibly/probably related to study drug 13 (39.4) 9 (26.5) 5 (15.2) 27 (27)
Leading to dose reduction or interruption 8 (24.2) 4 (11.8) 1 (3.0) 13 (13)
Premature withdrawals due to AEs 1 (3.0) 1 (2.9) 0 2 (2)
Anemia
All cases 17 (51.1) 11 (32.4) 9 (27.3) 37 (37)
Severe 5 (15.2) 2 (5.9) 1 (3.0) 8 (8)
Possibly/probably related to study drug 9 (27.3) 4 (11.8) 2 (6.1) 15 (15)
Leading to dose reduction or interruption 4 (12.1) 2 (5.9) 0 6 (6)
Premature withdrawals due to AEs 1 (3.0) 0 0 1 (1)
Sepsis (cytomegalovirus, infections)
All cases 16 (48.5) 11 (32.4) 8 (24.2) 35 (35)
Severe 1 (3.0) 1 (2.9) 2 (6.1) 4 (4)
Possibly/probably related to study drug 9 (27.3) 8 (23.5) 7 (21.2) 24 (24)
Leading to dose reduction or interruption 3 (9.1) 4 (11.8) 3 (9.1) 10 (10)
Premature withdrawals due to AEsa 0 0 2 (6.1) 2 (2)
Leukopenia
All cases 10 (30.3) 10 (29.4) 4 (12.1) 24 (24)
Severe 3 (9.1) 2 (5.9) 1 (3.0) 6 (6)
Possibly/probably related to study drug 10 (30.3) 8 (23.5) 4 (12.1) 22 (22)
Leading to dose reduction or interruption 10 (30.3) 8 (23.5) 4 (12.1) 22 (22)
Premature withdrawals due to AEs 0 0 0 0
a Includes one patient who died of hemorrhagic pancreatitis
Acute rejection has been reported to develop in
40–70% of pediatric renal recipients treated with a cy-
closporine/azathioprine regimen, the majority occurring
during the first 3 months post-transplantation.
Two deaths occurred among patients in this study;
neither death was considered related to MMF. The over-
all patient survival rate of 98% was comparable to that
reported among MMF-treated adult renal transplant re-
cipients (94.5%–96.4%) [8]. All patients experienced at
least one AE, as would be anticipated during the postop-
erative period in chronically ill children who are receiv-
ing intensive immunosuppressive therapy. The overall
level of immunosuppression, as well as the AE profiles
of the particular immunosuppressant drugs used, may
contribute to the types of AEs reported. For most AEs,
the types of events reported and the proportion of pa-
tients experiencing them were similar among the pediat-
ric age groups and also similar to those observed in adult
patients. However, certain adverse events (including di-
arrhea, anemia, leukopenia, and sepsis such as CMV and
infection) showed a trend toward higher incidence
among younger pediatric patients. Diarrhea is not an un-
common side effect of immunosuppression, occurring in
41% of patients given cyclosporine and corticosteroids
[20]. Additionally, the greater incidence of diarrhea in
younger patients may be related to the increased suscep-
tibility of this population (further augmented by immu-
nosuppressive therapy) to viral gastroenteritides [21],
which are clinically manifested predominantly as diar-
rheal illness. Nonetheless, in our study, despite the need
for dosage reduction due to diarrhea in some patients,
only two patients were withdrawn from the study for rea-
sons that included diarrhea.
Among the hematological AEs, anemia was reported
most frequently in the youngest age group, while the in-
cidence of leukopenia was greater among the youngest
and middle age groups. In addition to the potential im-
pact of renal dysfunction on the development of anemia
in this renal transplant population, the incidence of ane-
mia in the present study may be increased by other con-
tributing factors, including inadequate dietary iron intake
[22], blood loss due to phlebotomy, administration of im-
munosuppressants, and a bone marrow-suppressive ef-
fect of superimposed infections [22, 23]. Furthermore,
the youngest patients may experience an increased inci-
dence of anemia and leukopenia related to their greater
susceptibility to infection (particularly viral) due to the
absence of prior natural immunity. Most episodes of ane-
mia and leukopenia in this study were successfully man-
aged with modifications in study drug dosing. Only one
patient needed to withdraw from the study because of
anemia (<6 years old group), and none were withdrawn
because of leukopenia.
The overall immaturity of the pediatric immune
system, combined with administration of immunosup-
pressants, may account for the increased occurrence of
sepsis in the younger age group [21]. Although sepsis
(CMV, infections) occurred more frequently in the
youngest age group, the incidence that was considered
probably or possibly related to MMF was similar for the
three age groups, as was the proportion of patients for
whom this AE led to dose reduction or interruption. Only
two patients were withdrawn from the study because of
sepsis (both from the oldest age group). There were no
withdrawals due to sepsis among the youngest age
group, in which the incidence was greatest.
The pharmacokinetic data confirmed that the 
600 mg/m2 b.i.d. dosage (up to 1 g b.i.d.) of oral MMF
suspension achieved an MPA AUC0–12 in the early post-
transplantation period similar to that in adult renal trans-
plant patients receiving 1 g b.i.d. Also similar to adult re-
nal transplant patients, the pediatric patients had an in-
crease (1.9-fold) in MPA AUC0–12 and Cmax between day
7 and month 3, with a minimal increase (1.1-fold) be-
tween months 3 and 9.
In conclusion, administration of MMF 600 mg/m2
b.i.d. is effective in the prevention of acute rejection,
provides predictable pharmacokinetics, and is associated
with an acceptable safety profile in pediatric renal trans-
plant recipients.
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